Your browser doesn't support javascript.
loading
Association between the National Cancer Screening Programme (NSCP) for gastric cancer and oesophageal cancer mortality.
Kim, Jie-Hyun; Han, Kyung-Do; Lee, Jung Kuk; Kim, Hyun-Soo; Cha, Jae Myung; Park, Sohee; Kim, Joo Sung; Kim, Won Ho.
  • Kim JH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
  • Han KD; Department of Biostatistics, The Catholic University, Seoul, Korea.
  • Lee JK; Department of Biostatistics, Yonsei University Wonju College of Medicine, Wonju, Korea.
  • Kim HS; Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Korea. hyskim@yonsei.ac.kr.
  • Cha JM; Department of Internal Medicine, Kyung Hee University School of Medicine, Seoul, Korea.
  • Park S; The Department of Biostatistics, Graduate School of Public Health, Yonsei University, Seoul, Korea.
  • Kim JS; Department of Internal Medicine, Seoul National University School of Medicine, Seoul, Korea.
  • Kim WH; Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Br J Cancer ; 123(3): 480-486, 2020 08.
Article en En | MEDLINE | ID: mdl-32398860
ABSTRACT

BACKGROUND:

The aim was to evaluate whether this gastric cancer-screening programme was effective in reducing oesophageal cancer mortality.

METHODS:

A population-based retrospective cohort study was conducted using the Korean National Cancer Screening Programme (NCSP) database. The study cohort comprised 16,969 oesophageal cancer patients who had been diagnosed in 2007-2014. We analysed the association between the history of NSCP for gastric cancer and oesophageal cancer mortality.

RESULTS:

Compared with never-screened subjects, ever-screened subjects had an overall HR for oesophageal cancer mortality of 0.647 (95% CI, 0.617-0.679). According to the time interval since screening, the HRs of death were 0.731 (95% CI, 0.667-0.801) for 6-11 months, 0.635 (95% CI, 0.594-0.679) for 12-23 months, 0.564 (95% CI, 0.522-0.610) for 24-35 months and 0.742 (95% CI, 0.679-0.810) for ≥36 months. According to the last screening modality, the HRs of death were 0.497 (95% CI, 0.464-0.531) for upper endoscopy, and 0.792 (95% CI, 0.749-0.838) for UGIS. Upper endoscopy reduced the mortality consistently in all age groups over 50 years, whereas UGIS could not.

CONCLUSION:

The NCSP for gastric cancer was effective in reducing the mortality of oesophageal cancer, and upper endoscopy was superior to UGIS.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Endoscopía del Sistema Digestivo Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País como asunto: Asia Idioma: En Año: 2020 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias Gástricas / Neoplasias Esofágicas / Endoscopía del Sistema Digestivo Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged País como asunto: Asia Idioma: En Año: 2020 Tipo del documento: Article